About
Support the early Oncology clinical drug research and development process by providing strategic planning and execution, including clinical trial design and all aspects of descriptive, diagnostic, predictive and prescriptive analytics of data related to clinical projects like actual trial data, registries and real-world data bases. Represent biostatistics and coordinate the inputs from programing and data management at a substance/asset level regarding data science related aspects. Collaborat...
Updates & Highlights
Mexico Business News · 2 days ago
Global Growth Fuels Boehringer Ingelheim's Mexico Bet
Moomoo · 3 days ago
Suzhou Ribo Life Science: Milestone Payments From Boehringer Ingelheim SiRNA Deal Likely Also Boosted Revenue >6938.HK
creativeloafing.com · 7 days ago
Watch PAWty Presented by Boehringer Ingelheim
Recent Openings
View all 7 jobs arrow_forward(Senior) Principal Clinical Data Scientist
location_on Biberach an der Riß, BW, DE
All Jobs
(Senior) Principal Clinical Data Scientist
location_on Biberach an der Riß, BW, DE
Senior/Principal Clinical Data Scientist HTA
location_on Biberach an der Riß, BW, DE
SR AD/ AD, Principal Clinical Data Scientist -Early Oncology Drug Development (Remote)
location_on Ridgefield, CT, US
SR AD/ AD, Principal Clinical Data Scientist -Early Oncology Drug Development
location_on Ridgefield, CT, US
Culture & Mission
Benefits & Perks
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Boehringer Ingelheim?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentGlobal Growth Fuels Boehringer Ingelheim's Mexico Bet
Global Growth Fuels Boehringer Ingelheim's Mexico Bet
Mexico Business News · 2 days ago
Suzhou Ribo Life Science: Milestone Payments From Boehringer Ingelheim SiRNA Deal Likely Also Boosted Revenue >6938.HK
Suzhou Ribo Life Science: Milestone Payments From Boehringer Ingelheim SiRNA Deal Likely Also Boosted Revenue >6938.HK
Moomoo · 3 days ago
Watch PAWty Presented by Boehringer Ingelheim
Watch PAWty Presented by Boehringer Ingelheim
creativeloafing.com · 7 days ago
Sebastian Pohl on His 3 Year Completion of EACR-Boehringer Ingelheim Postdoctoral Fellowship
Sebastian Pohl on His 3 Year Completion of EACR-Boehringer Ingelheim Postdoctoral Fellowship
Oncodaily · 9 days ago
Foot & Mouth Disease US Supply Vaccines | Boehringer Ingelheim US
Foot & Mouth Disease US Supply Vaccines | Boehringer Ingelheim US
Boehringer Ingelheim · 10 days ago
Boehringer Ingelheim Achieves Human Animal Bond Certification
Boehringer Ingelheim Achieves Human Animal Bond Certification
The AI Journal · 16 days ago
Boehringer Ingelheim Advances Potential First-in-Class Triple Receptor Agonist BI 3034701 to Phase 2 for Obesity
Boehringer Ingelheim Advances Potential First-in-Class Triple Receptor Agonist BI 3034701 to Phase 2 for Obesity
BioPharm International · 16 days ago
Boehringer Ingelheim Achieves Human Animal Bond Certification
Boehringer Ingelheim Achieves Human Animal Bond Certification
Yahoo Finance · 17 days ago
Boehringer Ingelheim Achieves Human Animal Bond Certification
Boehringer Ingelheim Achieves Human Animal Bond Certification
PR Newswire · 17 days ago
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Carroll County Mirror-Democrat · 17 days ago
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
GlobeNewswire · 17 days ago
Innovation and Growth Drive First-Half 2026 Performance | Boehringer Ingelheim US
Innovation and Growth Drive First-Half 2026 Performance | Boehringer Ingelheim US
Boehringer Ingelheim · 18 days ago
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
Koreabizwire · 18 days ago
Kassenschlager Jardiance und US-Geschäft treiben Boehringer Ingelheim an
Kassenschlager Jardiance und US-Geschäft treiben Boehringer Ingelheim an
TradingView · 18 days ago
Boehringer Ingelheim reports first-half 2026 sales growth,
Boehringer Ingelheim reports first-half 2026 sales growth,
GlobeNewswire · 18 days ago
Boehringer Ingelheim Posts Sales Growth as Obesity Drug Filing Awaits
Boehringer Ingelheim Posts Sales Growth as Obesity Drug Filing Awaits
WSJ · 18 days ago
Boehringer Ingelheim's HY Net Sales Reach EUR 15.8 Billion
Boehringer Ingelheim's HY Net Sales Reach EUR 15.8 Billion
TradingView · 18 days ago
BioMed X and Boehringer Ingelheim Expand XSeed Labs
BioMed X and Boehringer Ingelheim Expand XSeed Labs
Scientist Live · 19 days ago
Boehringer Ingelheim standardises plant maintenance globally with osapiens
Boehringer Ingelheim standardises plant maintenance globally with osapiens
Manufacturing Chemist · 20 days ago
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
PMLiVE · 23 days ago